Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α) . Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research[1][2].